title: New oncology drugs and osteonecrosis of the jaw (ONJ).
authors.affiliation: Department of Biologic and Diagnostic Sciences, University of Tennessee Health Sciences Center, College of Dentistry, USA.
authors.forename: Cesar A
authors.initials: CA
authors.lastname: Migliorati
authors.forename: J Stansill
authors.initials: JS
authors.lastname: Covington
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects; D006801:Humans; D007571:Jaw Diseases / Q000209:etiology*; D010020:Osteonecrosis / Q000209:etiology*; D053245:RANK Ligand / Q000009:adverse effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab